The effect of domestic sorafenib is similar to that of imported drugs, and it can be used to treat patients with advanced renal cancer to achieve longer overall survival and progression-free survival, and the first-line and second-line treatments for advanced renal cancer have higher disease control rate, and the adverse effects are mostly tolerable. Sorafenib is a new type of oral small molecule tyrosine kinase receptor inhibitor, which mainly acts on vascular endothelial growth factor receptor growth factor receptor to inhibit tumor neoangiogenesis and tumor cell growth, and inhibits tumor cell proliferation by blocking RAF/MEK/ERK phosphorylation pathway. According to domestic and international studies, there are racial differences in the drug, and sorafenib may be more effective for patients in the Chinese population than in the Western population. The specific need to use Sorafenib, but also need to be based on the actual situation of the doctor to decide, the patient should listen to the doctor’s arrangements, do not unauthorized use of drugs, in order to avoid serious consequences.